

DAFTAR PUSTAKA

- Abraham Simatupang. (2017). *Statin (HMG-CoA reductase inhibitor): Bukti terbaru pengalaman penggunaannya*. Fakultas Kedokteran-Universitas Kristen Indonesia, 1-85.
- Arsana, P. M., Rosandi, R., Manaf, A., Budhiarta, A., Permana, H., Sucipta, K. W., Lindarto, D., Adi, S., Pramono, B., Harbuwono, D. S., Shahab, A., Sugiarto, Karimi, J., (Alm), L. B. P., Yuwono, A., & Suhartono, T. (2015). *Panduan Pengelolaan Dislipidemia Di Indonesia*. In *Perkumpulan Endokrinologi Indonesia (PERKENI)* (pp. 1–51).
- Carter, A. A., Gomes, T., Camacho, X., Juurlink, D. N., Shah, B. R., & Mamdani, M. M. (2013). *Risk of incident diabetes among patients treated with statins: Population based study*. *BMJ* (Online), 346(7911), 1–11. <https://doi.org/10.1136/bmj.f2610>
- Casula, M., Mozzanica, F., Scotti, L., Tragni, E., Pirillo, A., Corrao, G., & Catapano, A. L. (2017). *Statin use and risk of new-onset diabetes: A meta-analysis of observational studies*. *Nutrition, Metabolism and Cardiovascular Diseases*, 27(5), 396–406. <https://doi.org/10.1016/j.numecd.2017.03.001>
- Cederberg, H., Stančáková, A., Yaluri, N., Modi, S., Kuusisto, J., & Laakso, M. (2015). *Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort*. *Diabetologia*, 58(5), 1109–1117. <https://doi.org/10.1007/s00125-015-3528-5>
- Chamberlain, L. H. (2001). *Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes*. 507, 357–361.
- Chan, D. C., Pang, J., & Watts, G. F. (2015). *Pathogenesis and Management of the Diabetogenic Effect of Statins: a Role for Adiponectin and Coenzyme Q10?* *Current Atherosclerosis Reports*, 17(1). <https://doi.org/10.1007/s11883-014-0472-7>
- Choi, J. Y., Choi, C. U., Choi, B. G., Park, Y., Kang, D. O., Jang, W. Y., Kim, W., Na, J. O., Kim, J. W., Kim, E. J., Rha, S., Park, C. G., Seo, H. S., Jeong, M. H., Chae, S., Seong, I., Yoon, C., Cha, K. S., & Oh, S. K. (2021). *New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins*. 1–7.
- Coleman, C. I., Reinhart, K., Kluger, J., & White, C. M. (2008). *The effect of statins on the development of new-onset type 2 diabetes: A meta-analysis of randomized controlled trials*. *Current Medical Research and Opinion*, 24(5), 1359–1362. <https://doi.org/10.1185/030079908X292029>
- Engeda, J. C., Stackhouse, A., White, M., Rosamond, W. D., Lhachimi, S. K., Lund, J. L., Keyserling, T. C., & Avery, C. L. (2019). *Evidence of heterogeneity in statin-associated type 2 diabetes mellitus risk: A meta-analysis of randomized controlled trials and observational studies*. *Diabetes Research and Clinical*

- Practice, 151, 96–105. <https://doi.org/10.1016/j.diabres.2019.04.005>
- Erwinanto, Santoso, A., Putranto, J. N. E., Tedjasukmana, P., Suryawan, R., Rifqi, S., Kasiman, S., & Hak. (2013). *Pedoman tatalaksana dislipidemia. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI)*, 1–76.
- Farida, Y., & Claudia Putri. (2016). *Efek Penggunaan Simvastatin Terhadap Kenaikan Gula Darah Puasa Pasien Diabetes Melitus Tipe 2*. *Journal of Pharmaceutical Science and Clinical Research*, 01(01), 58–65. <https://doi.org/10.20961/jpscr.v1i1.696>
- Goldberg, R. B., Bittner, V. A., Dunbar, R. L., Fleg, J. L., Grunberger, G., Guyton, J. R., Leiter, L. A., McBride, R., Robinson, J. G., Simmons, D. L., Wysham, C., Xu, P., & Boden, W. E. (2016). *Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH*. *American Journal of Medicine*, 129(7), 753.e13-753.e22. <https://doi.org/10.1016/j.amjmed.2016.02.039>
- Golomb, B. A., & Evans, M. A. (2008). *Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism*. *American Journal of Cardiovascular Drugs*, 8(6), 373–418. <https://doi.org/10.2165/0129784-200808060-00004>
- Kadowaki, T., Yamauchi, T., Kubota, N., Hara, K., & Ueki, K. (2007). *Adiponectin and adiponectin receptors in obesity-linked insulin resistance*. *Novartis Foundation Symposium*, 116(7), 164–176. <https://doi.org/10.1002/9780470985571.ch15>
- Kawai, Y., Sato-Ishida, R., Motoyama, A., & Kajinami, K. (2011). *Place of pitavastatin in the statin armamentarium : promising evidence for a role in diabetes mellitus*. *Dovepress Journal*, 283–297. <https://doi.org/10.2147/DDDT.S13492>
- Laurence, D. ., & Bacharach, A. . (1964). *Evaluation of drug activities: pharmacometrics, 1th ed.* Academic Press. London. <http://eprints.umm.ac.id/42828/1/>.
- Laurie, kopin E. M. A., & Charles, J. L. M. (2017). *Dyslipidemia. American College of Physicians 2017*, 71(2), 275–279. <https://doi.org/10.7326/aitc201712050>
- Liu, W., Lin, C., Tsai, M., Cheng, C., Chen, S., Liou, J., Lin, W., Cheng, S., Lin, C., & Tsao, T. (2020). *biomedicines Effects of Pitavastatin , Atorvastatin , and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus : A Single-Center Cohort Study*. 1–12.
- Maki, K. C., Ridker, P. M., Brown, W. V., Grundy, S. M., & Sattar, N. (2014). *An assessment by the Statin diabetes safety task force: 2014 update*. *Journal of Clinical Lipidology*, 8(3 SUPPL), S17–S29. <https://doi.org/10.1016/j.jacl.2014.02.012>
- Mabuchi, H., Higashikata, T., Kawashiri, M., Katsuda, S., Mizuno, M., Nohara, A.,

- Inazu, A., Koizumi, J., & Kobayashi, J. (2005). *Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. Journal of Atherosclerosis and Thrombosis*, 12(2), 111–119. <https://doi.org/10.5551/jat.12.111>
- Marbawati, D., & Ikawati, B. (2009). *Kolonisasi Mus musculus albino Di Laboratorium Loka Litbang P2B2 Banjarnegara*. Balaba, 5 (1)(November), 1–5.
- Parida, S., Swain, T. R., Routray, S. N., & Maiti, R. (2017). *Effect of atorvastatin on glycaemic parameters in normoglycaemic and prediabetic subjects: A prospective, panel study. Journal of Clinical and Diagnostic Research*, 11(2), FC04–FC09. <https://doi.org/10.7860/JCDR/2017/23741.9427>
- Pedersen, T. R. (2010). *Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions*, 10 Suppl 1 (figure 1), 10–17. <https://doi.org/10.2165/1158822-S0-000000000-00000>
- Rha, S., Ph, D., Park, C. G., Ph, D., Kim, C. J., Ph, D., & Investigators, K. (2018). *Effect of pitavastatin compared with atorvastatin and rosuvastatin on new-onset diabetes mellitus in patients with acute myocardial infarction. The American Journal of Cardiology*. <https://doi.org/10.1016/j>
- Sampson, U. K., Linton, M. F., & Fazio, S. (2011). *Are statins diabetogenic? Current Opinion in Cardiology*, 26(4), 342–347. <https://doi.org/10.1097/HCO.0b013e3283470359>
- Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., Macfarlane, P. W., Packard, C. J., Stott, D. J., Westendorp, R. G., Shepherd, J., Davis, B. R., Pressel, S. L., Marchioli, R., Marfisi, R. M., Ford, I. (2010). *Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet*, 375(9716), 735–742. [https://doi.org/10.1016/S0140-6736\(09\)61965-6](https://doi.org/10.1016/S0140-6736(09)61965-6)
- Septiana, wayan chitra, & Ardiaria, M. (2016). *Efek pemberian seduhan kulit buah naga merah (Hylocereus polyrhizus) terhadap kadar malondialdehyde (MDA) tikus sprague dawley dislipidemia. Journal of Nutrition*, 5(jilid 2), 344–352.
- Sherwood, L. (2012). *Fisiologis Manusia Dari Sel Ke Sistem (6th ed.)*. Jakarta EGC.
- Sudrajad, G. B., Kusuma, A. S., & Kusumaratna, R. K. (2020). *Paradigma baru penggunaan statin: efek kardioprotektif atau penyebab onset baru diabetes melitus? Jurnal Biomedika Dan Kesehatan*, 3(2), 101–108. <https://doi.org/10.18051/jbiomedkes.2020.v3.101-108>
- Takaguri, A., Satoh, K., Itagaki, M., Tokumitsu, Y., & Ichihara, K. (2008). *Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. Journal of Pharmacological Sciences*, 107(1), 80–89. <https://doi.org/10.1254/jphs.FP0072403>

- Talbert, R. ., Dipiro, J. ., Yee, G . matzke, G.R., Wells, B. ., & Posey, L. (2008). *dyslipidemia*. 1–16.
- Taylor, F., Huffman, M., Macedo, A., Moore, T., Burke, M., Devey, smith G., Ward, K., & Ebrahim, S. (2013). *Statins for primary prevention of cardiovascular disease*. *Annals of Internal Medicine*, *171*(1), 73–74. <https://doi.org/10.7326/L19-0261>
- Wahjuni, S. (2015). *Dislipidemia menyebabkan stress oksidatif ditandai oleh meningkatnya malondialdehid*. Udayana University Press, Denpasar-Bali.
- Thakker, D., Nair, S., Pagada, A., Jamdade, V., & Malik, A. (2016). *Statin Use And The Risk Of Developing Diabetes: a network meta-analysis*. *Pharmacoepidemiology and Drug Safety*, 1–19. <https://doi.org/10.1002/pds>
- Yoon, D., Sheen, S. S., Lee, S., Choi, Y. J., Park, R. W., & Lim, H. (2016). *Statins and risk for new-onset diabetes mellitus*. 0(October).
- Zhao, W., & Zhao, S. P. (2015). *Different effects of statins on induction of diabetes mellitus: An experimental study*. *Drug Design, Development and Therapy*, *9*, 6211–6223. <https://doi.org/10.2147/DDDT.S87979>